NASDAQ:ACCD

Accolade - ACCD Stock Forecast, Price & News

$11.96

-0.31 (-2.53%)

(As of 03/17/2023 08:53 PM ET)

Add

Compare

Today's Range: $11.76
▼
$12.41
50-Day Range: $7.74
▼
$13.30
52-Week Range: $4.61
▼
$19.39

Volume: 685,300 shs
Average Volume: 726,425 shs
Market Capitalization: $870.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.25

Institutional Ownership

Accolade MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 10.8% Upside
$13.25 Price Target
Short Interest: Healthy
4.30% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.70
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$15,838 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($6.49) to ($2.07) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Business Services Sector

106th out of 318 stocks

Business Services, Not Elsewhere Classified Industry

38th out of 93 stocks

3.3

Analyst's Opinion

Consensus Rating
Accolade has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 8 buy ratings, 8 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.25, Accolade has a forecasted upside of 10.8% from its current price of $11.96.
Amount of Analyst Coverage
Accolade has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
4.30% of the outstanding shares of Accolade have been sold short.
Short Interest Ratio / Days to Cover
Accolade has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in Accolade has recently decreased by 0.95%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Accolade does not currently pay a dividend.
Dividend Growth
Accolade does not have a long track record of dividend growth.

4.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Accolade has received a 80.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private general practice doctor's diagnostic online appointments", "Private oncologist's appointments", "Private neurologist's appointments", and "Private otolaryngologist's appointments" products. See details.
Environmental Sustainability
The Environmental Impact score for Accolade is -0.70.

1.3

News and Social Media Coverage

News Sentiment
Accolade has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Business Services companies.
Search Interest
Only 2 people have searched for ACCD on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Accolade to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,838.00 in company stock.
Percentage Held by Insiders
Only 7.30% of the stock of Accolade is held by insiders.
Percentage Held by Institutions
79.01% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Accolade are expected to grow in the coming year, from ($6.49) to ($2.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Accolade is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Accolade is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Accolade has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Accolade (NASDAQ:ACCD) Stock

Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.

Receive ACCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter.

ACCD Stock News Headlines

March 6, 2023 | finance.yahoo.com

Accolade Welcomes Lyra Health to Its Trusted Partner Ecosystem

March 5, 2023 | finance.yahoo.com

Should You Investigate Accolade, Inc. (NASDAQ:ACCD) At US$13.30?

March 20, 2023 | Weiss Ratings (Ad)

Fed's Shocking New Plan to Control Your Money

The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 

February 16, 2023 | finance.yahoo.com

An Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 31% Undervalued

February 16, 2023 | finance.yahoo.com

Michael Hilton Joins Accolade Board of Directors

February 2, 2023 | finance.yahoo.com

Analyst Initiates Coverage On Accolade, Says 'Differentiated In Growing Market'

January 31, 2023 | finance.yahoo.com

With stock up 14%, Insiders of Accolade, Inc. (NASDAQ:ACCD) must be wishing they had bought more last year

January 13, 2023 | finance.yahoo.com

Why Shares of Accolade Soared This Week

March 20, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

January 12, 2023 | benzinga.com

Accolade's Return On Capital Employed Overview

January 12, 2023 | seekingalpha.com

Accolade stock surges 20% as FQ3 revenue rises 9% Y/Y; provides fiscal 2023 outlook

January 12, 2023 | markets.businessinsider.com

BTIG Keeps Their Hold Rating on Accolade (ACCD)

January 10, 2023 | finance.yahoo.com

Accolade Analyst Finds Stock Attractively Valued Post Q3 Beat, T-5 Contract Win

January 10, 2023 | finance.yahoo.com

Analysts Stay Bullish On Accolade Stock, Call Q3 Earnings Better Than Expected Amid Challenging Backdrop

January 9, 2023 | finance.yahoo.com

Accolade Announces Results for Fiscal Third Quarter 2023

January 4, 2023 | finance.yahoo.com

Accolade Announces Participation in 25th Annual Needham Growth Conference

December 20, 2022 | finance.yahoo.com

Accolade to Announce Fiscal Third Quarter 2023 Financial Results

November 14, 2022 | finance.yahoo.com

Accolade Champions Health Equity and Welcomes FOLX Health to Trusted Partner Ecosystem at HLTH 2022

October 17, 2022 | seekingalpha.com

Accolade: Inching Closer To Profitability (NASDAQ:ACCD) - Seeking Alpha

October 10, 2022 | uk.finance.yahoo.com

Accolade (NASDAQ:ACCD) investors are sitting on a loss of 70% if they invested a year ago - Yahoo Finance UK

October 10, 2022 | finance.yahoo.com

Accolade (NASDAQ:ACCD) investors are sitting on a loss of 70% if they invested a year ago

October 9, 2022 | reuters.com

Ronaldo goalscoring accolades continue as he reaches 700 club mark - Reuters.com

October 8, 2022 | seekingalpha.com

Accolade, Inc. (ACCD) Q2 2023 Earnings Call Transcript

October 7, 2022 | streetinsider.com

Accolade Announces Results for Fiscal Second Quarter 2023 - StreetInsider.com

October 7, 2022 | finance.yahoo.com

Accolade Posts Narrower Quarterly Loss, Tightens Annual Sales Guidance - Yahoo Finance

October 7, 2022 | seekingalpha.com

Accolade Inc. (ACCD) Q2 2023 Results - Earnings Call Transcript - Seeking Alpha

October 6, 2022 | investing.com

Accolade Tops Q2 EPS by 6c By Investing.com - Investing.com

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ACCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter.

ACCD Company Calendar

Last Earnings: 1/09/2023
Today: 3/20/2023
Next Earnings (Estimated): 4/27/2023
Fiscal Year End: 2/29/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Business services, not elsewhere classified
Sub-Industry: N/A
Sector: Business Services
Current Symbol: NASDAQ:ACCD
CUSIP: N/A
CIK: 1481646
Web: accolade.com
Phone: 206-926-8100
Fax: N/A
Employees: 2,350
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.25
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +10.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 16 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-123,120,000.00
Net Margins: -129.59%
Pretax Margin: -129.51%
Return on Equity: -28.47%
Return on Assets: -16.65%

Debt

Debt-to-Equity Ratio: 0.58
Current Ratio: 3.14
Quick Ratio: 3.14

Sales & Book Value

Annual Sales: $357.87 million
Price / Sales: 2.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $12.78 per share
Price / Book: 0.94

Miscellaneous

Outstanding Shares: 72,787,000
Free Float: 67,474,000
Market Cap: $870.53 million
Optionable: Not Optionable
Beta: 1.62

Key Executives

Mr. Rajeev Singh (Age 55)
Chairman & CEO
Comp: $847.24k

Mr. Robert Cavanaugh (Age 54)
Pres
Comp: $644.93k

Mr. Stephen H. Barnes CPA (Age 51)
CFO & Treasurer
Comp: $602.66k

Mr. Michael W. Hilton (Age 58)
Chief Innovation Officer
Comp: $598.39k

Mr. Todd Friedman
Sr. VP of Investor Relations

Mr. Richard Eskew
EVP, Gen. Counsel, CCO & Sec.

Ms. Carolina Lobo
Chief Marketing Officer

Ms. Kristen Keating Weeks
Sr. VP of Strategy, Corp. Devel. & Partnerships

Ms. Jennifer Hanson
Exec. VP of People and Culture & Chief HR Officer

Mr. Todd Clardy
Exec. VP & GM of Mid-Market Bus.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACCD Stock - Frequently Asked Questions

Should I buy or sell Accolade stock right now?: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last year. There are currently 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACCD shares.
View ACCD analyst ratings or view top-rated stocks.
What is Accolade's stock price forecast for 2023?: 16 Wall Street research analysts have issued 1 year price targets for Accolade's stock. Their ACCD share price forecasts range from $9.00 to $16.00. On average, they anticipate the company's share price to reach $13.25 in the next year. This suggests a possible upside of 10.8% from the stock's current price.
View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts.
How have ACCD shares performed in 2023?: Accolade's stock was trading at $7.79 at the beginning of the year. Since then, ACCD shares have increased by 53.5% and is now trading at $11.96.
View the best growth stocks for 2023 here.
When is Accolade's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our ACCD earnings forecast.
How were Accolade's earnings last quarter?: Accolade, Inc. (NASDAQ:ACCD) released its earnings results on Monday, January, 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.05. The firm had revenue of $90.95 million for the quarter, compared to the consensus estimate of $87.53 million. Accolade had a negative trailing twelve-month return on equity of 28.47% and a negative net margin of 129.59%. The company's revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.31 earnings per share.
What ETFs hold Accolade's stock?: ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares Micro-Cap ETF (IWC).iShares U.S. Healthcare Providers ETF (IHF).
What guidance has Accolade issued on next quarter's earnings?: Accolade issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97.00 million-$101.00 million, compared to the consensus revenue estimate of $101.71 million.
What is Rajeev Singh's approval rating as Accolade's CEO?: 152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Accolade own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include Honeywell International (HON), CVS Health (CVS), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC).
When did Accolade IPO?: (ACCD) raised $176 million in an IPO on Thursday, July 2nd 2020. The company issued 8,800,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.
What is Accolade's stock symbol?: Accolade trades on the NASDAQ under the ticker symbol "ACCD."
Who are Accolade's major shareholders?: Accolade's stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (7.50%), Brown Advisory Inc. (6.93%), Geode Capital Management LLC (1.70%), Millennium Management LLC (1.51%), Bank of America Corp DE (1.09%) and Sumitomo Mitsui Trust Holdings Inc. (1.08%). Insiders that own company stock include Michael W Hilton, Rajeev Singh, Robert N Cavanaugh, Stephen H Barnes and Thomas J Neff.
View institutional ownership trends.
How do I buy shares of Accolade?: Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Accolade's stock price today?: One share of ACCD stock can currently be purchased for approximately $11.96.
How much money does Accolade make?: Accolade (NASDAQ:ACCD) has a market capitalization of $870.53 million and generates $357.87 million in revenue each year. The company earns $-123,120,000.00 in net income (profit) each year or ($6.65) on an earnings per share basis.
How many employees does Accolade have?: The company employs 2,350 workers across the globe.
How can I contact Accolade?: Accolade's mailing address is 660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING PA, 19462. The official website for the company is accolade.com. The company can be reached via phone at 206-926-8100 or via email at ir@accolade.com.

This page (NASDAQ:ACCD) was last updated on 3/20/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Accolade - ACCD Stock Forecast, Price & News

Accolade MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Accolade (NASDAQ:ACCD) Stock

ACCD Stock News Headlines

ACCD Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACCD Stock - Frequently Asked Questions

Overall MarketRank^™